Waller, P; Evans, S; (2011) Mediator: who's to blame? Lancet, 377 (9782). pp. 2002-2003. ISSN 0140-6736 DOI: https://doi.org/10.1016/S0140-6736(11)60860-X Full text not available from this repository.

Goldacre, B; (2009) Is the conflict of interest unacceptable when drug companies conduct trials on their own drugs? Yes. BMJ (Clinical research ed), 339. b4949. ISSN 0959-8138 DOI: https://doi.org/10.1136/bmj.b4949

Chauhan, D; Miners, AH; Fischer, AJ; (2007) Exploration of the difference in results of economic submissions to the National Institute of Clinical Excellence by manufacturers and assessment groups. International journal of technology assessment in health care, 23 (1). pp. 96-100. ISSN 0266-4623 DOI: https://doi.org/10.1017/S0266462307051628

Brugha, R; (2003) Antiretroviral treatment in developing countries: the peril of neglecting private providers. BMJ (Clinical research ed), 326 (7403). pp. 1382-4. ISSN 0959-8138 DOI: https://doi.org/10.1136/bmj.326.7403.1382

Klausner, RD; Fauci, AS; Corey, L; Nabel, GJ; Gayle, H; Berkley, S; Haynes, BF; Baltimore, D; Collins, C; Douglas, RG; +14 more... Esparza, J; Francis, DP; Ganguly, NK; Gerberding, JL; Johnston, MI; Kazatchkine, MD; McMichael, AJ; Makgoba, MW; Pantaleo, G; Piot, P; Shao, Y; Tramont, E; Varmus, H; Wasserheit, JN; (2003) Medicine. The need for a global HIV vaccine enterprise. Science (New York, NY), 300 (5628). pp. 2036-9. ISSN 0036-8075 DOI: https://doi.org/10.1126/science.1086916 Full text not available from this repository.

Buse, K; Waxman, A; (2001) Public-private health partnerships: a strategy for WHO. Bulletin of the World Health Organization, 79 (8). pp. 748-54. ISSN 0042-9686 https://researchonline.lshtm.ac.uk/id/eprint/15619

Evans, S; Pocock, S; (2001) Societal responsibilities of clinical trial sponsors - Lack of commercial pay off is not a legitimate reason for stopping a trial. BMJ (Clinical research ed), 322 (7286). pp. 569-70. ISSN 0959-8138 https://researchonline.lshtm.ac.uk/id/eprint/16654

Shretta, R; Walt, G; Brugha, R; Snow, RW; (2001) A political analysis of corporate drug donations: the example of Malarone((R)) in Kenya. Health policy and planning, 16 (2). pp. 161-70. ISSN 0268-1080 https://researchonline.lshtm.ac.uk/id/eprint/16387 Full text not available from this repository.